Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Dova Pharmaceuticals

Nasdaq:DOVA
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DOVA
Nasdaq
$808M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The last earnings update was 2 days ago. More info.


Add to Portfolio Compare Print
  • Dova Pharmaceuticals has significant price volatility in the past 3 months.
DOVA Share Price and Events
7 Day Returns
0.2%
NasdaqGM:DOVA
0.7%
US Pharmaceuticals
0.5%
US Market
1 Year Returns
82.2%
NasdaqGM:DOVA
-5.5%
US Pharmaceuticals
12.8%
US Market
DOVA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dova Pharmaceuticals (DOVA) 0.2% -0.1% 93.1% 82.2% - -
US Pharmaceuticals 0.7% 2.4% 4.3% -5.5% 12.7% 5.7%
US Market 0.5% 4.3% 8% 12.8% 38.7% 44.5%
1 Year Return vs Industry and Market
  • DOVA outperformed the Pharmaceuticals industry which returned -5.5% over the past year.
  • DOVA outperformed the Market in United States of America which returned 12.8% over the past year.
Price Volatility
DOVA
Industry
5yr Volatility vs Market

Value

 Is Dova Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Dova Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $28.04.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dova Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dova Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:DOVA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-2.61
NasdaqGM:DOVA Share Price ** NasdaqGM (2019-11-11) in USD $28.04
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 30 Publicly-Listed Pharmaceuticals Companies 16.4x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 18.24x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dova Pharmaceuticals.

NasdaqGM:DOVA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:DOVA Share Price ÷ EPS (both in USD)

= 28.04 ÷ -2.61

-10.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dova Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Dova Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Dova Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:DOVA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
71%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.18x
United States of America Market PEG Ratio Median Figure of 2,023 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Dova Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Dova Pharmaceuticals's assets?
Raw Data
NasdaqGM:DOVA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $1.15
NasdaqGM:DOVA Share Price * NasdaqGM (2019-11-11) in USD $28.04
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 180 Publicly-Listed Pharmaceuticals Companies 2.96x
United States of America Market PB Ratio Median Figure of 5,070 Publicly-Listed Companies 1.73x
NasdaqGM:DOVA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:DOVA Share Price ÷ Book Value per Share (both in USD)

= 28.04 ÷ 1.15

24.31x

* Primary Listing of Dova Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dova Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Dova Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Dova Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Dova Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
71%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dova Pharmaceuticals expected to grow at an attractive rate?
  • Dova Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Dova Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Dova Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:DOVA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:DOVA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 71%
NasdaqGM:DOVA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 63.6%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.5%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:DOVA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:DOVA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 388 151 1
2022-12-31 217 54 1
2021-12-31 100 -12 1
2020-12-31 40 -61 2
2019-12-31 16 -70 2
2019-11-14
NasdaqGM:DOVA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 14 -65 -74
2019-06-30 13 -58 -72
2019-03-31 14 -54 -75
2018-12-31 10 -54 -72
2018-09-30 8 -41 -62
2018-06-30 5 -32 -52
2018-03-31 -21 -38
2017-12-31 -11 -30
2017-09-30 -7 -37
2016-12-31 -1 -36

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Dova Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Dova Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:DOVA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Dova Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:DOVA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.53 3.53 3.53 1.00
2022-12-31 1.31 1.31 1.31 1.00
2021-12-31 -0.32 -0.32 -0.32 1.00
2020-12-31 -1.78 -1.63 -1.92 2.00
2019-12-31 -2.42 -2.39 -2.44 2.00
2019-11-14
NasdaqGM:DOVA Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -2.61
2019-06-30 -2.56
2019-03-31 -2.65
2018-12-31 -2.60
2018-09-30 -2.29
2018-06-30 -1.98
2018-03-31 -1.61
2017-12-31 -1.40
2017-09-30 -1.93
2016-12-31 -2.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Dova Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Dova Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dova Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Dova Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dova Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dova Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Dova Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Dova Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Dova Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dova Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:DOVA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 13.73 -74.06 66.92 17.90
2019-06-30 13.29 -72.30 64.76 18.56
2019-03-31 14.36 -74.89 67.82 18.56
2018-12-31 10.36 -72.28 62.33 17.89
2018-09-30 7.51 -62.25 52.48 14.31
2018-06-30 4.58 -52.45 39.58 15.95
2018-03-31 -38.30 22.92 14.73
2017-12-31 -29.96 13.62 15.59
2017-09-30 -37.32 8.08 26.81
2016-12-31 -36.25 1.60 27.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Dova Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Dova Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Dova Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Dova Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dova Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Dova Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dova Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dova Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Dova Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dova Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dova Pharmaceuticals Company Filings, last reported 1 month ago.

NasdaqGM:DOVA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 33.24 30.84 68.45
2019-06-30 50.81 20.70 76.78
2019-03-31 63.29 20.84 92.70
2018-12-31 76.36 20.61 104.95
2018-09-30 94.20 20.38 122.03
2018-06-30 109.72 20.15 134.70
2018-03-31 125.10 0.00 126.90
2017-12-31 61.18 30.31 94.87
2017-09-30 67.61 27.12 100.41
2016-12-31 6.80 13.64 28.71
  • Dova Pharmaceuticals's level of debt (92.8%) compared to net worth is high (greater than 40%).
  • Unable to establish if Dova Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Dova Pharmaceuticals has sufficient cash runway for 1.1 years based on current free cash flow.
  • Dova Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 76.1% each year.
X
Financial health checks
We assess Dova Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dova Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Dova Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Dova Pharmaceuticals dividends.
If you bought $2,000 of Dova Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Dova Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Dova Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:DOVA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1948 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:DOVA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-11-14

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Dova Pharmaceuticals has not reported any payouts.
  • Unable to verify if Dova Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Dova Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Dova Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Dova Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dova Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dova Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Dova Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Dova Pharmaceuticals has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the Dova Pharmaceuticals management team in years:

1.6
Average Tenure
  • The average tenure for the Dova Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Kevin Laliberte

TITLE
Senior Vice President of Product Development
COMPENSATION
$1M
AGE
41
TENURE
2.7 yrs

Jason Levine

TITLE
Vice President of Marketing
TENURE
0.7 yrs

Ilija Zlatar

TITLE
Head of U.S. Sales
TENURE
0.7 yrs

Lee Allen

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
67
TENURE
2.6 yrs
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Aug 19 Buy Paul Manning Individual 09. Aug 19 09. Aug 19 28,062 $15.87 $445,344
12. Jul 19 Buy Perceptive Advisors LLC Company 09. Jul 19 11. Jul 19 85,104 $16.89 $1,419,612
09. Jul 19 Buy Perceptive Advisors LLC Company 05. Jul 19 05. Jul 19 50,000 $16.46 $823,000
04. Jul 19 Buy Perceptive Advisors LLC Company 01. Jul 19 03. Jul 19 20,541 $16.67 $298,005
01. Jul 19 Buy Perceptive Advisors LLC Company 27. Jun 19 28. Jun 19 427,209 $14.48 $5,703,209
08. Mar 19 Buy Paul Manning Individual 07. Mar 19 07. Mar 19 68,000 $7.48 $508,640
21. Dec 18 Buy Paul Manning Individual 21. Dec 18 21. Dec 18 128,500 $7.10 $832,050
21. Dec 18 Buy David Zaccardelli Individual 20. Dec 18 20. Dec 18 10,000 $6.07 $60,700
21. Dec 18 Buy Roger Jeffs Individual 19. Dec 18 20. Dec 18 30,000 $6.25 $186,635
21. Dec 18 Buy Mark Hahn Individual 19. Dec 18 19. Dec 18 2,500 $6.28 $15,700
21. Dec 18 Buy Sean Stalfort Individual 20. Dec 18 20. Dec 18 31,000 $6.26 $194,060
20. Dec 18 Buy Paul Manning Individual 20. Dec 18 20. Dec 18 266,631 $6.17 $1,645,113
X
Management checks
We assess Dova Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dova Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Analysts Expect Breakeven For Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)

Dova Pharmaceuticals, Inc.'s (NASDAQ:DOVA): Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. … View our latest analysis for Dova Pharmaceuticals DOVA is bordering on breakeven, according to the 5 Pharmaceuticals analysts. … Next Steps: There are too many aspects of DOVA to cover in one brief article, but the key fundamentals for the company can all be found in one place – DOVA’s company page on Simply Wall St.

Simply Wall St -

Does The Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) Share Price Tend To Follow The Market?

(NASDAQ:DOVA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … What this means for you: Beta only tells us that the Dova Pharmaceuticals share price is sensitive to broader market movements.

Simply Wall St -

Those Who Purchased Dova Pharmaceuticals (NASDAQ:DOVA) Shares A Year Ago Have A 68% Loss To Show For It

While not a mind-blowing move, it is good to see that the Dova Pharmaceuticals, Inc. … Check out our latest analysis for Dova Pharmaceuticals Because Dova Pharmaceuticals is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at.

Simply Wall St -

Dova Pharmaceuticals, Inc.'s (NASDAQ:DOVA) Profit Outlook

Dova Pharmaceuticals, Inc.'s (NASDAQ:DOVA):. … Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. … As path to profitability is the topic on DOVA’s investors mind, I’ve decided to gauge market sentiment.

Simply Wall St -

Read This Before Selling Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) Shares

We often see insiders buying up shares in companies that perform well over the long term. … So we'll take a look at whether insiders have been buying or selling shares in Dova Pharmaceuticals, Inc. … It's quite normal to see company insiders, such as board members, trading in company stock, from time to time.

Simply Wall St -

Should You Consider Dova Pharmaceuticals, Inc. (NASDAQ:DOVA)?

(NASDAQ:DOVA) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of DOVA, it

Simply Wall St -

Loss-Making Dova Pharmaceuticals Inc (NASDAQ:DOVA) Expected To Breakeven

The US$519m market-cap posted a loss in its most recent financial year of -US$30m and a latest trailing-twelve-month loss of -US$52m leading to an even wider gap between loss and breakeven. … I’ve put together a brief outline of industry analyst expectations for DOVA, its year of breakeven and its implied growth rate … See our latest analysis for Dova Pharmaceuticals

Simply Wall St -

Dova Pharmaceuticals Inc's (NASDAQ:DOVA) Shift From Loss To Profit

Dova Pharmaceuticals Inc's (NASDAQ:DOVA):. … Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. … The US$962.17m market-cap posted a loss in its most recent financial year of -US$29.95m and a latest trailing-twelve-month loss of -US$38.30m leading to an even wider gap between loss and breakeven

Simply Wall St -

Dova Pharmaceuticals Inc's (NASDAQ:DOVA) Profit Outlook

Many investors are wondering the rate at which DOVA will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for DOVA, its year of breakeven and its implied growth rate. … See our latest analysis for Dova Pharmaceuticals DOVA is bordering on breakeven, according to analysts. … DOVA currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Simply Wall St -

Breaking Down Dova Pharmaceuticals Inc's (NASDAQ:DOVA) Ownership Structure

NasdaqGM:DOVA Insider_trading Apr 5th 18 General Public Ownership The general public holds a substantial 19.71% stake in DOVA, making it a highly popular stock among retail investors. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in DOVA should also look at another important group of investors: private companies, with a stake of 0.18%, who are primarily invested because of strategic and capital gain interests.

Simply Wall St -

Company Info

Description

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company’s lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Details
Name: Dova Pharmaceuticals, Inc.
DOVA
Exchange: NasdaqGM
Founded: 2016
$807,604,238
28,801,863
Website: http://www.dova.com
Address: Dova Pharmaceuticals, Inc.
240 Leigh Farm Road,
Suite 245,
Durham,
North Carolina, 27707,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM DOVA Common Stock Nasdaq Global Market US USD 29. Jun 2017
DB 0AV Common Stock Deutsche Boerse AG DE EUR 29. Jun 2017
Number of employees
Current staff
Staff numbers
115
Dova Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/14 00:29
End of day share price update: 2019/11/11 00:00
Last estimates confirmation: 2019/11/13
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.